Approximately 20% of all colorectal cancers contain wild KRAS (the absence of a mutation on the KRAS oncogene) [25, 26, 27, 28] and only tumours which express the wild-type KRAS can be candidates for cetuximab, while the patients with mutant KRAS are considered resistant. This evidence concerns the gene KRAS and colorectal cancer.